Aduro Biotech Announces Poster Presentations of Phase 2 Pancreatic Cancer and Phase 1B Mesothelioma Clinical Trials at American Society of Clinical Oncology

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Aduro BioTech, Inc. announces two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Dr. Raffit Hassan, Head of the Solid Tumor Immunotherapy Section at the Laboratory of Molecular Biology at the National Cancer Institute, will present data from Aduro’s Phase 1B clinical trial in patients with malignant pleural mesothelioma (ClinicalTrials.gov Identifier: NCT01675765). Dr. Dung Le, Assistant Professor of Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, will present results from the safety and efficacy analysis of Aduro’s Phase 2 clinical trial in patients with metastatic pancreatic cancer (ClinicalTrials.gov Identifier: NCT01417000).

Help employers find you! Check out all the jobs and post your resume.

Back to news